|Bid||7.36 x 1000|
|Ask||0.00 x 3000|
|Day's Range||6.97 - 7.63|
|52 Week Range||4.00 - 29.31|
|Beta (5Y Monthly)||1.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2022 - Nov 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Nov 10, 2010|
|1y Target Est||20.08|
And Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark) announced that ...
Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) ("Bausch Health") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), are pleased to announce that RYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray) has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.1
Bausch Health (TSX:BHC)(NYSE:BHC) stock is climbing back with the separation of its Bausch + Lomb shares looking imminent. The post 1 Canadian Stock up 30% in a Month and Climbing appeared first on The Motley Fool Canada.